Clinical Trial Detail

NCT ID NCT03434418
Title A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Duke University
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: adult senior

No variant requirements are available.